Sartorius Stedim Biotech's Evaluation Adjusted Amid Strong Financial Metrics and Growth Potential

Sartorius Stedim Biotech SA, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently experienced an adjustment in evaluation. This revision reflects a notable shift in the company's quality score, which has drawn attention to its underlying financial metrics.
Over the past five years, Sartorius Stedim Biotech has demonstrated a sales growth rate of 13.46%, while its EBIT growth has been recorded at 3.54%. The company's EBIT to interest ratio stands at 7.14, indicating a solid capacity to cover interest expenses. Additionally, the debt to EBITDA ratio is at 1.85, and the net debt to equity ratio is relatively low at 0.52, suggesting a manageable level of debt.

The firm has a tax ratio of 19.67% and a dividend payout ratio of 38.14%, which reflects its commitment to returning value to shareholders. The average return on capital employed (ROCE) is reported at 24.27%, and the return on equity (ROE) averages 21.32%.

These metrics provide a comprehensive view of Sartorius Stedim Biotech's current financial standing and market position, highlighting the factors contributing to the recent evaluation adjustment.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.